News articles about Shire (NASDAQ:SHPG) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.2576575338782 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- How Is Bioverativ’s Alprolix Positioned Now? (finance.yahoo.com)
- Shire to separate ADHD drugs before possible spin-off, cuts 2020 target (finance.yahoo.com)
- Shire cuts sales outlook; still considering spinout of ADHD drugs (finance.yahoo.com)
- Shire To Operate As Two Divisions: Rare Disease And Neuroscience (markets.businessinsider.com)
- Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
SHPG has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a report on Friday, October 27th. Cantor Fitzgerald reissued a “buy” rating and set a $222.00 price objective on shares of Shire in a research report on Friday, October 27th. Liberum Capital raised shares of Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, ValuEngine raised shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $212.18.
Shares of Shire (SHPG) traded down $0.86 during midday trading on Friday, reaching $147.55. 1,098,141 shares of the company traded hands, compared to its average volume of 1,202,044. Shire has a twelve month low of $137.17 and a twelve month high of $192.15. The company has a market cap of $44,560.00, a PE ratio of 27.79, a price-to-earnings-growth ratio of 0.84 and a beta of 1.59. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The business had revenue of $3.70 billion for the quarter. During the same period in the previous year, the business posted $3.17 EPS. Shire’s revenue was up 7.1% compared to the same quarter last year. equities analysts predict that Shire will post 15 EPS for the current fiscal year.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.